Table 1 Clinical characteristics and survival outcome of the study patients with LARCC
Case | Sex | Age (years) | Site of colon cancer | Adjacent organ infiltration on preoperative CT | Preoperative therapy | Operation | LOS (days) | Complications | Adjuvant therapy | Survival (months) | Status | Cause of death |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 48 | ASC | Du + Pa | – | RHCPD | 18 | PF(C), IAA | – | 35 | Dead | Recurrence |
2 | F | 44 | HF | Du + Pa + SMV | FOLFOX4 | RHCPD + SMVR | 18 | – | Capecitabine | 112 | Alive | |
3 | M | 48 | HF | Du + L | – | RHCPD | 22 | PF(B), IAA | mFOLFOX6 | 103 | Alive | |
4 | M | 60 | HF | Du | – | RHCPD | 45 | IB | – | 16 | Dead | Recurrence |
5 | M | 75 | HF | Du | – | RHCPD | 26 | PF(B), IAA | – | 36 | Dead | Recurrence |
6 | M | 62 | ASC | Du | – | RHCPD | 21 | PF(A) | XELOX | 9 | Dead | Recurrence |
7 | F | 36 | HF | Du | mFOLFOX6 | RHCPD | 15 | – | FOLFIRI | 69 | Alive | |
8 | F | 65 | HF | Du | – | RHCPD | 16 | PF(A) | XELOX | 63 | Alive | |
9 | M | 45 | HF | Du | – | RHCPD | 21 | PF(B), IAA | FOLFOX4 | 9 | Dead | Recurrence |
10 | M | 73 | HF | Du | – | RHCPD | 36 | BF | – | 41 | Dead | Recurrence |
11 | M | 35 | HF | Du | – | RHCPD | 15 | PF(A) | XELOX | 48 | Alive | |
12 | M | 65 | HF | Du + Pa | – | RHCPD | 26 | PF(A) | XELOX | 47 | Alive | |
13 | F | 46 | HF | Du | – | RHCPD | 20 | BF, IAA | XELOX | 41 | Alive | |
14 | M | 54 | HF | Du + L | FOLFOXIRI + BEV | RHCPD | 43 | Ileus | FOLFOXIRI + BEV | 30 | Alive | |
15 | M | 63 | ASC | Du | – | RHCPD | 26 | – | XELOX | 23 | Alive | |
16 | F | 42 | HF | Du + Pa | XELOX + BEV + Pem | RHCPD | 24 | PF(A) | XELOX + BEV + Pem | 20 | Alive | |
17 | M | 64 | HF | Du | – | RHCPD | 11 | – | XELOX | 17 | Alive | |
18 | F | 66 | HF | Du | – | RHCPD | 25 | PF(A) | XELOX | 8 | Alive | |
19 | F | 65 | HF | Du | – | RHCPD | 13 | – | XELOX | 5 | Alive |